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(in-hospital mortality; 7.0 %). In addition to traditional pre-
dictors of in-hospital death, statin-treated dyslipidemia was 
a favorable predictor of in-hospital mortality for STEMI 
and NSTEMI patients, whereas hemodialysis was the 
strongest predictor for NSTEMI patients.
Keywords ST elevation myocardial infarction · Non-ST 
elevation myocardial infarction · In-hospital mortality · 
Risk factors
Introduction
Acute myocardial infarction (AMI) is a major cause of 
morbidity and mortality worldwide. The direct relation-
ship between higher survival rates of ST elevation myo-
cardial infarction (STEMI) patients and the earlier pri-
mary PCI can be performed has been well established [1, 
2]. Current updated guidelines for non-STEMI (NSTEMI) 
in Japan, US, and Europe recommend an early invasive 
strategy within 24-h for high-risk patients defined as a 
GRACE score of >140 [3, 4]. However, little data regarding 
NSTEMI time courses is available in Japan.
The Tokyo CCU network is a well-organized cardiac 
care network. All 67 hospitals participating in the Tokyo 
CCU network have as a goal to perform emergency PCI 
within 1 h from arrival at the hospital. Deducing from the 
regional distribution of these 67 hospitals, the Tokyo CCU 
network probably includes 95 % of all patients who had 
an AMI within the greater Tokyo area, moreover there are 
13 million people in the Tokyo metropolitan area. Fur-
thermore, gathering data from this cardiac care network 
on the current practices and in-hospital survival rates is 
vital to better serve the highly populated Tokyo metropol-
itan area.
Abstract Limited data exists on ST-segment eleva-
tion myocardial infarction (STEMI) and non-STEMI 
(NSTEMI) managed by a well-organized cardiac care net-
work in a metropolitan area. We analyzed the Tokyo CCU 
network database in 2009–2010. Of 4329 acute myocardial 
infarction (AMI) patients including STEMI (n = 3202) and 
NSTEMI (n = 1127), percutaneous coronary intervention 
(PCI) was performed in 88.8 % of STEMI and 70.4 % of 
NSTEMI patients. Mean onset-to-door and door-to-bal-
loon times in STEMI patients were shorter than those in 
NSTEMI patients (167 vs 233 and 60 vs 145 min, respec-
tively, p < 0.001). Coronary artery bypass graft surgery 
was performed in 4.2 % of STEMI and 11.4 % of NSTEMI 
patients. In-hospital mortality was significantly higher 
in STEMI patients than NSTEMI patients (7.7 vs 5.1 %, 
p < 0.007). Independent correlates of in-hospital mortal-
ity were advanced age, low blood pressure, and high Killip 
classification, statin-treated dyslipidemia and PCI within 
24 h were favorable predictors for STEMI. High Kil-
lip classification, high heart rate, and hemodialysis were 
significant predictors of in-hospital mortality, whereas 
statin-treated dyslipidemia was the only favorable predic-
tor for NSTEMI. In conclusion, patients with MI received 
PCI frequently (83.5 %) and promptly (door-to-balloon 
time; 66 min), and had favorable in-hospital prognosis 
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The aim of the present study was to clarify current char-
acteristics, managements, time courses, and in-hospital out-
comes in STEMI and NSTEMI patients in the Tokyo CCU 
network registered cohort within the contemporary real-
world setting.
Methods
The Tokyo CCU network registry
The Tokyo CCU network was established in 1978 with 
the goal to treats patients with emergency cardiovascular 
events as promptly as possible, with the help of ambulance 
units dispatched through the Tokyo Fire Department [5]. 
The Tokyo CCU network database is an continually ongo-
ing multicenter registry that prospectively collects infor-
mation regarding emergency admissions to acute care 
facilities [6, 7]. The Tokyo CCU network was originally 
comprised of 12 major participating hospitals in 1978. 
Today it is comprised of 67 hospitals, serving a popula-
tion of 13 million in the Tokyo metropolitan area (Fig. 1). 
Because all data is anonymously catalogued, informed 
consents are not required. In accordance with rules set 
forth by the Ministry of Internal Affairs and Communi-
cations, patient data collection policies are displayed at 
the emergency entrance of each individual Tokyo CCU 
network institution. The registry’s purpose and mission are 
displayed on pamphlets, which also explain CCU personal 
information protections to emergency admission patients 
and their families. Data collection was performed via indi-
vidual chart review by trained data collection personnel. 
The quality of submitted data is maintained through annual 
data quality checks which include point-of-entry mecha-
nistic controls. No extramural funding was used to support 
this work. Each Tokyo CCU network hospital is accredited 
by the Metropolitan Tokyo Government and participates 
in the Tokyo citywide system of acute cardiac care (acute 
myocardial infarction, unstable angina, arrhythmia, acute 
heart failure, aortic dissection, and pulmonary embolism).
Patients and data collection
This study was performed using Tokyo CCU network regis-
tered cohort data collected from January 2009 to December 
2010. Only the data of patients with AMI were selected. 
Clinical diagnoses of STEMI and NSTEMI, based on the 
2007 universal definition, was made by individual cardi-
ologists at Tokyo CCU network institutions [8]. All patients 
were prospectively registered at admission. For this study, 
STEMI and NSTEMI were redefined as the follow; STEMI, 
patients must have had chest symptoms, ST-segment eleva-
tion in 2 contiguous leads or left bundle branch block, and 
an elevated biochemical marker of myocardial necrosis 
Fig. 1  Japanese and Tokyo map. This map shows the regional distribution of 67 hospitals participating in Tokyo CCU network
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(troponin T >0.1 ng/ml or creatine phosphokinase twofold 
the upper limit of normal); NSTEMI, patients must have 
had chest symptoms, ST-segment depression or T-wave 
inversion in 2 contiguous leads, and an elevated biochemi-
cal marker of myocardial necrosis. AMI patients that did 
not fulfill either definition in present study were excluded. 
The therapeutic strategies of STEMI and NSTEMI 
depended on the practice of each individual institution and 
individual cardiologist. However, all patients were treated 
based on guidelines set forth by the Japanese Circulation 
Society and ACC/AHA for the diagnosis and treatment of 
AMI [2, 3].
Clinical course information, as well as the diagnostic 
and therapeutic management of patients entering the regis-
try, was obtained by means of a standardized questionnaire 
made by the steering committee. The following data was 
collected on patients with STEMI and NSTEMI: (1) time 
courses from onset of symptoms to admission to cardiovas-
cular care unit and coronary revascularization; (2) patients’ 
demographics, presenting characteristics, personal and/or 
family history of cardiovascular disease, and cardiovascular 
risk factors; (3) cardiovascular treatments during the hospi-
talization; (4) in-hospital all-cause death. Completed case 
report forms were checked by the Tokyo CCU network 
scientific committee for the validity and consistency of the 
data compiled.
For this study, 5291 consecutive patients were identified 
that satisfied STEMI and NSTEMI definition. However, 
data from 962 patients was incomplete and those cases 
were excluded from the analysis. Therefore data from the 
remaining 4329 patients were analyzed.
Statistical analysis
Categorical variables were tested using the Chi-square test 
or, if not applicable, Fisher’s exact test. Continuous vari-
ables are presented as means and standard deviations and 
were tested using the Student’s t test or the Mann–Whitney 
U test. To identify predictors of in-hospital mortality, uni-
variate and multivariate logistic regression analyses were 
performed with 3 models: model 1 was derived from the 
overall cohort, model 2 was derived from STEMI patients, 
and model 3 was derived from NSTEMI patients. Selected 
variables were advanced age, male gender, systolic blood 
pressure, heart rate, Killip classification, percutaneous 
coronary intervention (PCI) of 24 h from onset, smok-
ing, diabetes mellitus, dyslipidemia treated with statin, 
hyperuricemia, past MI, history of heart failure (HF), old 
cerebral infarction (CI), hemodialysis, and history of PCI. 
Only variables with a p value ≤0.05 identified with univari-
ate analysis were entered as explanatory variables in sub-
sequent multivariate models. All probability values were 2 
tailed, and values of p < 0.05 were considered statistically 
significant. Statistical analysis was performed using IBM 
SPSS statistics 20 (IBM corporation, Armonk, NY, USA).
Results
Patients’ demographics
Clinical patient characteristics are summarized in Table 1. 
The average age was 68 years old, and 74.6 % were male. 
Approximately, two-thirds had hypertension, 40 % dyslipi-
demia, one-third diabetes mellitus, and one-third were cur-
rent smokers. With regards to location of onset, 67.8 % of 
patients experienced their first attack at home, 22 % away 
from home, 5.9 % in a hospital, and 4.2 % were unknown.
When comparing subgroups, NSTEMI patients were 
typically older than those with STEMI. Moreover, 
NSTEMI patients were more likely to have history of car-
diovascular disease and additional coronary risk factors 
with the exception to hemodialysis patients, those with dys-
lipidemia, and/or are current smokers. The distribution of 
Killip classification and location of onset were statistically 
similar between the 2 groups. Of the patients with PCI for 
which time course information was available (n = 3266), 
the median onset-to-door time (the median time interval 
between the onset of symptom and the patient’s hospital 
arrival) was 180 min. The interval was longer in NSTEMI 
patients (n = 714) than in STEMI patients (n = 2554) 
(median time was 233 vs 165 min; p < 0.001). The median 
door-to-balloon time (the median time interval between 
the patient’s arrival at the hospital and flow restoration by 
means of balloon inflation) was 60 and 145 min in STEMI 
(n = 1969) and NSTEMI (n = 432), respectively. Of 
STEMI patients (n = 1969), 68.2 % (n = 1343) and 90.5 % 
(n = 1784) underwent primary PCI within 90 min and 6 h 
upon arrival to the hospital, respectively. The appropriate-
ness of primary PCI was analyzed based on US guideline 
of appropriate use criteria for coronary revascularization 
[9]. Of STEMI patients, to which primary PCI was avail-
able to onset-to-balloon time (n = 1473), 89.4 % of these 
patients (n = 1318) received primary PCI within 12 h from 
onset of symptom.
Management and outcome
Table 2 shows the use of pharmacological therapies dur-
ing hospitalization. Heparin was administered as an anti-
coagulant therapy to 87.9 % of patients, whereas, aspirin 
was prescribed as antiplatelet therapy to 93.6 %. Eighty 
percent of patients who underwent PCI received dual anti-
platelet therapy (DAPT) during their admission. Angio-
tensin-converting enzyme inhibitor (ACEI)/angiotensin II 
receptor blocker (ARB), β blocker, and calcium antagonists 
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were prescribed to approximately 60, 40, and 20 % of all 
patients, respectively. Statin was administered to 65 % of 
all patients. In-hospital pharmacological therapies were 
used more frequently in STEMI patients than NSTEMI 
patient, with the exception of calcium antagonists, where 
its use was higher in NSTEMI. In STEMI patients, the pro-
portion of thrombolytic therapy including facilitated PCI 
and thrombolysis alone was just 3.1 % (data not shown).
Angiographic findings, invasive procedures, time courses, 
and in-hospital deaths are shown in Table 3. Most patients 
(92.2 %) underwent coronary angiography. Culprit lesions 
included the right coronary artery and the left anterior 
descending artery in a majority of STEMI patients, whereas 
culprit lesions involved the left main trunk, left circumflex 
artery, and undefined lesions appeared more frequently 
in NSTEMI patients than STEMI patients. Of NSTEMI 
patients, 55.2 % had multi vessel diseases, and almost the 
same proportion of STEMI patients (55.4 %) had single ves-
sel disease. With respect to invasive procedures, 83.5 % of 
all patients underwent PCI during hospitalization; STEMI 
Table 1  Patients’ clinical 
characteristics
STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarc-
tion, BMI body mass index, BP blood pressure, HR heart rate, MI myocardial infarction, PCI percutaneous 
coronary intervention, CABG coronary artery bypass graft, PAD peripheral artery disease
Total (n = 4329) STEMI (n = 3202) NSTEMI (n = 1127) p value
Age (years) 67.9 ± 13.0 67.3 ± 13.1 69.5 ± 12.5 <0.001
Male (%) 74.6 75.5 72.3 0.041
BMI (kg/m2) 23.7 ± 4.0 23.7 ± 3.8 23.8 ± 4.5 0.203
Systolic BP (mmHg) 134.6 ± 36.7 133.1 ± 40.6 140.3 ± 29.4 <0.001
HR (beat/min) 79.5 ± 21.2 79.0 ± 21.8 81.0 ± 19.5 0.014
Cardiovascular history
 MI (%) 9.2 7.3 13.7 <0.001
 PCI (%) 8.1 6.6 11.7 <0.001
 CABG surgery (%) 1.9 1.0 4.0 <0.001
 Heart failure (%) 1.7 1.3 2.6 0.017
 Cerebral infarction (%) 5.7 5.3 6.7 0.118
 Hemodialysis (%) 3.9 2.1 8.0 <0.001
 PAD (%) 1.5 1.3 2.2 0.064
Coronary risk factor
 Hypertension (%) 61.9 60.9 64.4 0.059
 Dyslipidemia (%) 43.4 43.5 43.1 0.847
 Diabetes mellitus (%) 32.5 31.1 36.0 0.006
 Current smoker (%) 32.9 34.3 29.6 0.009
 Hyperuricemia (%) 5.1 5.1 5.3 0.795
Location of onset
 Home 67.8 66.8 70.2 0.527
 Outside the house 22.0 24.1 17.2
 In hospital 5.9 5.2 7.7
 Unknown 4.2 3.9 4.9
Killip classification
 Class 1 (%) 74.6 74.3 75.6 0.402
 Class 2 (%) 13.4 13.2 14.0
 Class 3 (%) 5.4 4.7 7.1
 Class 4 (%) 6.5 7.8 3.3
Time course
 Onset-to-Door (n = 3266) (n = 2554) (n = 714)
  Median time (min) 180 165 233 <0.001
  Interquartile range (min) 80–475 74–423 110–653
 Door-to-Ballon time (n = 2401) (n = 1969) (n = 432)
  Median time (min) 66 60 145 <0.001
  Interquartile range (min) 39–130 35–104 61–681
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and NSTEMI patients accounted for 88.8 and 70.4 % of all 
patients, respectively (p < 0.001). Of all patients who under-
went PCI, bare metal stents and drug eluting stents were 
inserted in 60.0 and 27.0 %, respectively. Bypass surgery 
was performed more frequently in NSTEMI patients than 
STEMI patients (11.4 vs. 4.2 %, respectively, p < 0.001).
Table 2  Pharmacological 
therapies during hospitalization
DAPT dual antiplatelet therapy, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor 
blocker
Total (n = 3241) STEMI (n = 2221) NSTEMI (n = 1020) p value
Heparin (%) 87.9 88.8 85.8 0.015
Aspirin (%) 93.6 94.6 91.3 <0.001
Thienopyridine (%) 73.1 77.4 63.6 <0.001
DAPT 71.7 76.2 62.0 <0.001
PCI with DAPT 80.7 82.1 76.6 0.002
Statin (%) 65.0 68.6 57.2 <0.001
ACEI/ARB (%) 58.3 61.5 51.4 <0.001
Nitrate (%) 44.2 44.8 42.9 0.32
β blocker (%) 38.8 41.7 32.5 <0.001
Nicorandil (%) 41.5 46.0 31.7 <0.001
Diuretic (%) 23.2 23.5 22.6 0.62
Calcium antagonist (%) 17.6 15.2 22.7 <0.001
Oral antidiabetic drug (%) 9.8 10.1 9.1 0.41
Insulin (%) 6.5 6.2 7.4 0.22
Table 3  Angiographic findings, 
invasive procedures, and 
in-hospital outcome
BMS bare metal stent, DES drug eluting stent
Total (n = 4329) STEMI (n = 3202) NSTEMI (n = 1127) p value
Angiographic findings
 CAG (%) 92.2 94.1 87.7 <0.001
 Culprit lesion <0.001
  RCA 34.5 38.7 23.4
  LMT 3.3 2.6 5.2
  LAD 45.2 47.8 37.9
  LCX 13.9 9.7 25.2
  Others 0.5 0.2 1.3
  Undefined 2.6 0.9 6.9
 The number of diseased vessels <0.001
  Single vessel 52.9 55.4 44.8
  Multi vessel 47.1 44.6 55.2
Treatment
 PCI (%) 83.5 88.8 70.4 <0.001
  PCI within 24 h (%) 73.2 81.1 53.7 <0.001
  Thrombus Aspiration (%) 55.1 61.9 28.3 <0.001
  Distal protection device (%) 7.5 8.1 4.8 0.006
 The type of stent <0.001
  BMS 60.0 64.2 46.6
  DES 27.0 22.4 41.7
  Unknown 13.0 13.4 11.7
 CABG (%) 6.3 4.2 11.4 <0.001
 IABP 12.2 11.5 14.0 0.039
 PCPS 3.6 4.1 1.9 <0.001
Outcome
 In-hospital mortality (%) 7.0 7.7 5.1 0.007
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STEMI patients had significantly a higher in-hospi-
tal mortality rate than NSTEMI patients (7.5 vs. 5.1 %, 
p = 0.007) (Table 4).
Multivariate analysis
After logistic regression analysis, independent prognos-
ticators of in-hospital mortality in STEMI patients were: 
advanced age, low blood pressure, and high Killip clas-
sification; whereas statin-treated dyslipidemia and PCI 
performed within 24 h from onset were associated lower 
risk of death (Table 5). For NSTEMI patients, independ-
ent prognosticators of in-hospital mortality were: high 
heart rate, high Killip classification, and hemodialysis 
(Table 6); whereas statin-treated dyslipidemia was the 
only factor associated with lowering risk of death. Inde-
pendent predictors of in-hospital mortality in AMI patients 
were very comparable to prognosticators for STEMI and 
NSTEMI (Table 4). Killip classification was the strong-
est predictor of in-hospital mortality in all groups. Since 
statin-treated dyslipidemia was associated with lowering 
risk of death, we compared patients with statin-treated 
dyslipidemia to patients without dyslipidemia. STEMI 
patient with statin-treated dyslipidemia had more Killip 
1 than patients without dyslipidemia, however, this was 
not the case in NSTEMI patients. More frequently than 
patients without dyslipidemia, both STEMI and NSTEMI 
patients with stain-treated dyslipidemia received PCI 
within 24 h. Door-to-balloon time was similar between 
cases with stain-treated dyslipidemia and without dyslipi-
demia in both STEMI and NSTEMI patients. Excluding 
history of cerebral infarction, the history of cardiovascu-
lar disease and coronary risk factors were similar among 
cases with stain-treated dyslipidemia and without dys-
lipidemia in STEMI and NSTEMI patients. Cases without 
dyslipidemia had more history of cerebral infarction than 
cases with stain-treated dyslipidemia in both STEMI and 
NSTEMI patients groups (data not shown).
Discussion
To the best of our knowledge, the Tokyo CCU network 
is the largest citywide, most well-organized cardiac care 
system for a metropolitan city area in the world. This 
citywide, multicenter, prospective observational registry 
provides insight on the characteristics, management, and 
in-hospital mortality rates of both STEMI and NSTEMI 
patients. NSTEMI patients tended to have more extensive 
medical histories, including more cardiovascular events 
and coronary risk factors, than STEMI patients. Never-
theless, NSTEMI patients tended to receive in-hospital 
Table 4  Univariate and multivariate logistic regression analysis
Statistical significant values (p < 0.05) in multivariate analysis are highlighted in bold
AMI patients (n = 2724)
Univariate Multivariate
Odd ratio (95 % CI) p value Odd ratio (95 % CI) p value
Dependent variable; in-hospital mortality
Independent variable
 Age (per 1-year increase) 1.056 (1.045–1.067( <0.001 1.048 (1.030–1.066) <0.001
 Male 0.631 (0.492–0.809) <0.001 0.744 (0.499–1.110) 0.147
 Systolic BP (per 10 mmHg increase) 0.982 (0.978–0.987) <0.001 0.993 (0.987–0.998) 0.011
 HR (per decile) 1.173 (1.115–1.235) <0.001 1.073 (1.009–1.142) 0.025
 STEMI 1.555 (1.156–2.092) 0.004 1.582 (0.980–2.558) 0.060
 Killip 3.019 (2.713–3.359) <0.001 2.515 (2.155–2.936) <0.001
 PCI within 24 h 0.462 (0.363–0.589) <0.001 1.073 (1.009–1.142) 0.144
 Smoking 0.424 (0.309–0.582) <0.001 0.954 (0.613–1.482) 0.833
 Diabetes mellitus 1.243 (0.961–1.609) 0.097
 Dyslipidemia treated with statin (reference; no dyslipidemia) 0.236 (0.161–0.346) <0.001 0.365 (0.223–0.596) 0.045
 Hyperuricemia 1.240 (0.732–2.101) 0.424
 Prior MI 1.805 (1.256–2.594) 0.001 1.447 (0.818–2.560) 0.205
 History of heart failure 2.769 (1.432–5.355) 0.002 0.994 (0.405–2.445) 0.990
 Old cerebral infarction 2.045 (1.347–3.104) 0.001 1.169 (0.631–2.168) 0.619
 Hemodialysis 2.496 (1.542–4.040) <0.001 2.294 (1.107–4.753) 0.026
 History of PCI 1.507 (1.028–2.209) 0.036 1.346 (0.743–2.445) 0.327
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Table 5  Univariate and multivariate logistic regression analysis
Statistical significant values (p < 0.05) in multivariate analysis are highlighted in bold
STEMI patients (n = 2133)
Univariate Multivariate
Odd ratio (95 % CI) p value Odd ratio (95 % CI) p value
Dependent variable; in-hospital mortality
Independent variable
 Age (per 1-year increase) 1.069 (1.055–1.081) <0.001 1.058 (1.037–1.079) <0.001
 Male 0.506 (0.385–0.665) <0.001 0.703 (0.450–1.098) 0.121
 Systolic BP (per 10 mmHg increase) 0.773 (0.724–0.826) <0.001 0.865 (0.792–0.946) <0.001
 HR (per decile) 1.157 (1.095–1.222) <0.001 1.046 (0.978–1.119) 0.190
 Killip 3.105 (2.757–3.498) <0.001 2.570 (2.167–3.049) <0.001
 PCI within 24 h 0.335 (0.254–0.441) <0.001 0.625 (0.406–0.962) 0.033
 Smoking 0.370 (0.258–0.529) <0.001 0.913 (0.547–1.523) 0.727
 Diabetes mellitus 1.156 (0.865–1.546) 0.327 –
 Dyslipidemia treated with statin (reference; no dyslipidemia) 0.198 (0.127–0.310) <0.001 0.376 (0.217–0.651) <0.001
 Hyperuricemia 1.347 (0.777–2.430) 0.274 –
 Prior MI 1.508 (0.947–2.400) 0.084 –
 History of heart failure 3.044 (1.389–6.673) 0.005 0.917 (0.322–2.616) 0.872
 Old cerebral infarction 2.091 (1.303–3.355) 0.002 1.061 (0.531–2.120) 0.867
 Hemodialysis 2.374 (1.190–4.734) 0.014 1.610 (0.583–4.448) 0.359
 History of PCI 1.407 (0.876–2.259) 0.157 –
Table 6  Univariate and multivariate logistic regression analysis
Statistical significant values (p < 0.05) in multivariate analysis are highlighted in bold
NSTEMI patients (n = 646)
Univariate Multivariate
Odd ratio (95 % CI) p value Odd ratio (95 % CI) p value
Dependent variable; in-hospital mortality
Independent variable
 Age (per 1-year increase) 1.015 (0.993–1.038) 0.182 –
 Male 1.637 (0.837–3.203) 0.150 –
 Systolic BP (per 10 mmHg increase) 0.973 (0.850–1.113) 0.688 –
 HR (per decile) 1.290 (1.123–1.482) <0.001 1.165 (1.012–1.342) 0.034
 Killip 2.617 (2.045–3.348) <0.001 2.420 (1.727–3.392) <0.001
 PCI within 24 h 0.728 (0.416–1.274) 0.267 –
 Smoking 0.695 (0.349–1.383) 0.300 –
 Diabetes mellitus 1.833 (1.025–3.280) 0.041 1.205 (0.550–2.641) 0.641
 Dyslipidemia treated with statin (reference; no dyslipidemia) 0.415 (0.194–0.887) 0.023 0.368 (0.139–0.977) 0.045
 Hyperuricemia 0.771 (0.182–3.270) 0.724 –
 Prior MI 3.390 (1.805–6.368) <0.001 1.691 (0.638–4.485) 1.691
 History of heart failure 2.715 (0.783–9.410) 0.115 –
 Old cerebral infarction 2.080 (0.850–5.091) 0.109 –
 Hemodialysis 3.838 (1.872–7.870) <0.001 3.627 (1.326–9.920) 0.012
 History of PCI 2.217 (1.122–4.379) 0.022 1.582 (0.585–4.275) 0.366
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pharmacological therapies and undergo PCI less frequently 
than STEMI patients. These tendencies are not unique to 
Tokyo CCU network and are similar to many registries in 
Japan and other countries [10–12].
For this study, we focused on the comparing in-hospital 
mortality with previous studies performed in other coun-
tries. In the other studies, the in-hospital mortality rate was 
4.6–8.9 % in STEMI and 4.2–5.8 % in NSTEMI [11–14], 
thus our results are comparable to other various large and/or 
small-scale registries. However, the approach to the manage-
ment of coronary revascularization in Japan is unique and 
comparisons made between the Tokyo CCU network and 
foreign registries are unreliable. Therefore, we compared 
our data with the most notable registry in Japan, namely, 
the Prevention of AtherothrombotiC Incidents Following 
Ischemic Coronary attack (PACIFIC) registry. The PACIFIC 
registry is comprised of 96 Japanese regional core hospitals, 
that have the facilities for advanced interventional therapy, 
participating in a large-scale, prospective observational 
study [10]. In the PACIFIC registry, in-hospital mortality 
for STEMI and non-ST elevation acute coronary syndrome 
(which includes NSTEMI and unstable angina) was 4.1 and 
1.3 %, respectively. The PACIFIC registry data was charac-
terized by a high proportion of patients of who received PCI 
(93.5 %) and low proportions of Killip class 3 and 4 (2.9 
and 2.8 %, respectively), which contrasts with the present 
study. Whereas, all participating PACIFIC registry hospitals 
were regional core hospitals and had facilities for advanced 
interventional therapy, Tokyo CCU network hospitals have 
varying degrees of different capabilities. Roughly 30 % of 
Tokyo CCU network hospitals have fewer than 4 beds in the 
CCU, are incapable of performing emergency cardiovascu-
lar surgery, and come across less than 200 PCIs annually. 
Generally, to perform PCI, many Japanese hospitals with a 
cardiology unit have their own catheterization laboratories. 
Accordingly, primary PCI is performed in what may be con-
sidered relatively small-scale hospitals. In terms of hospital 
size and capability, we believe that our registry reflects more 
closely the real-world clinical data of a Japanese metropoli-
tan area. Of particular note, there was a higher proportion of 
NSTEMI patients with hemodialysis (8.0 %) for this study. 
It is known that Japan has one of the highest hemodialysis 
rates when compared with elsewhere in the world [15, 16], 
and correspondingly patients with chronic kidney disease on 
hemodialysis have higher rates of cardiovascular morbidity 
and mortality [17].
With regards to onset-to-door times, there are two main 
components that may potentially cause delays; the pre-hos-
pital patient decision delay and pre-hospital transportation 
delay [18]. According to several studies about patient delay in 
Europe and the US, it remains a controversial topic whether 
education campaigns significantly contribute to delay reduc-
tions from onset to hospital arrival [19–21]. Furthermore, the 
pre-hospital transportation delay depends largely on the emer-
gency medical service response time in Tokyo. The median 
time interval from first medical contact to hospital presenta-
tion was 37 min in the Tokyo CCU network (data not shown 
as table). This time interval is acceptable, but streamlining the 
process of hospital selection may be needed.
With regards to pharmacological therapies, β blocker 
was prescribed to fewer patients in comparison to the 
French OPERA registry [12]. However, β blocker utiliza-
tion rates in Japan are generally lower than that of Western 
countries, even though favorable β blocker effects on AMI 
have been reported [22–25]. The plausible explanation for 
lower β blocker utilization is that the cardiovascular event 
rate after AMI for Japanese patients is lower than that of 
Western patients and coronary spasm incidences for Japa-
nese patients is higher than that of Western patients [26]. 
Nicorandil utilization rates were extremely high in this 
study (44.2 %). The J-wind study in Japan showed that 
nicorandil had a favorable effect for acute MI patients and 
improved the left ventricular ejection fraction even though 
it did not reduce infarct size or the incidence of cardiac 
death [27]. Consequently, there factors may affect the 
selection of medications.
Multivariate logistic regression analysis showed that 
statin-treated dyslipidemia was associated with lower risk 
in both STEMI and NSTEMI patients. These findings lend 
further support to the effectiveness of statin treatment in 
STEMI and NSTEMI [28, 29]. Additionally, PCI per-
formed within 24-h was associated with lower in-hospital 
mortality rates in STEMI patients. It is well established 
that primary PCI is greatly beneficial for STEMI [1, 2]. 
In contrast, the optimal intervention time for the treatment 
of NSTEMI patients has been debated for years [30–32]. 
Several randomized trials have shown that in NSTEMI 
patients, an early-intervention strategy was not superior to 
a delayed-intervention strategy for the prevention of death 
[31, 32]. On the other hand, recent updated guidelines for 
NSTEMI recommended an early invasive strategy within 
24-h for high-risk patients defined as GRACE score of 
>140 [3, 4]. In this study’s NSTEMI data, there was no 
statistical superiority between survival rates for PCI per-
formed within 24-h versus PCI performed after 24 h. A rea-
son for our findings in multivariate logistic regression is the 
inclusion of all patients, but not selected patients.
These study findings have clinical implications and can 
provide much information to cardiologists. At the level of 
statistical significance, the second strongest predictor of in-
hospital mortality was hemodialysis in NSTEMI patients. 
Therefore, cardiologists and nephrologists must pay greater 
attention in cases involving the cardiovascular events of 
patients with hemodialysis.
Furthermore, current STEMI guidelines recommend 
a door-to-balloon time of 90 min or less for patients 
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undergoing primary PCI [2, 33]. Door-to-balloon time in 
this study was shorter than that of recommended guide-
lines, and approximately 70 % of patients were prepared 
to undergo primary PCI within 90 min upon arrival to the 
hospital. Moreover, according to US guidelines of appropri-
ate use criteria [9], coronary revascularization is appropriate 
12 h or less from the onset of symptoms for STEMI patients. 
For this study, 89.4 % of patients were appropriately eligi-
ble to receive primary PCI based on US guideline of appro-
priate use criteria for coronary revascularization. Thus the 
promptness and appropriateness of primary PCI were within 
acceptable parameters. Nevertheless, in-hospital mortal-
ity in this study was not particularly low. Approaches with 
the potential to improve in-hospital mortality may include 
reducing the number of patients with door-to-balloon times 
greater than 90 min, increasing the patients’ awareness of 
symptoms, and shorting the transfer time between first med-
ical contact and hospital presentation.
Limitations
The present study is subject to some intrinsic limitations 
associated with an observational study. Patients that did 
not need to be hospitalized in the CCU were not registered 
in this study, therefore, low-risk patients may have been 
excluded. Since we redefined the STEMI and NSTEMI as 
troponin T >0.1 ng/ml in this study, there were some una-
vailable and missing data for each patient existed. Of 962 
patients who were excluded, 63.5 % were not described 
as having STEMI or NSTEMI. A proportion of excluded 
patients underwent PCI within 24 h upon arrival to the 
hospital were lower than those of study patients (68.8 
vs. 73.2 %, p = 0.06). The distribution of Killip class for 
excluded patients was markedly different from those of 
study patients (1, 69.0 %; 2, 13.4 %; 3, 7.6 %; 4, 10.0 %; 
p = 0.010). In-hospital mortality rate of excluded patients 
was higher than that of study patients (10.9 vs. 7.0 %, 
p < 0.001). Therefore, severe patient cases may have been 
excluded, and selection bias may have affected the results. 
Moreover, the number of registered patients varied widely 
among hospitals. Thus, large institutional variations may 
have occurred. In addition, important pieces of informa-
tion such as long-term outcomes and events, left ventric-
ular ejection fraction (LVEF), medication doses, and the 
initiation times of medications were not assessed in the 
present study. Within the present study, we showed that 
statin-treated dyslipidemia was associated with a lower 
risk of in-hospital mortality when compared to patients 
with no dyslipidemia. However, it remains unknown 
whether the effect was due to early or continuing sta-
tin treatment. Though it is important to describe in detail 
ST-segment change (ST-segment elevation, left bundle 
branch block, ST-segment depression, or T-wave inver-
sion), details of ST-segment change were not evaluated in 
this study. Moreover, the usage rate of drug eluting stent 
(DES) was low in this study. In 2009–2010, many cardi-
ologists recognized that the stent thrombosis rate of first-
generation DES was increasing year by year [34–36]. The 
second generation of DES (such as the Everolimus-eluting 
stent) was released in Japan in 2010. Thus, many cardiolo-
gists may have avoided implanting DES to AMI patients 
due to these reasons.
Despite these limitations, we believe that our find-
ings regarding acute situations in MI patients are accurate 
reflections within the contemporary DES and Troponin era 
in Tokyo.
Conclusions
This metropolitan observational study revealed that STEMI 
and NSTEMI patients have different characteristics, man-
agements, and prognoses. Compared with NSTEMI patient, 
those with STEMI generally have shorter door-to-balloon 
times, a higher proportion of PCI, more optimal medical 
therapy, but higher in-hospital mortality rates. In addition to 
the traditional negative independent predictors of in-hospital 
mortality such as age or Killip Classification, PCI performed 
within 24 h from onset and statin-treated dyslipidemia were 
positively associated with favorable in-hospital outcomes in 
STEMI patients. In contrast, for NSTEMI patients, PCI per-
formed within 24 h from onset was proved to be the only 
positive factor to lower risk of in-hospital mortality. Moreo-
ver, in addition to the negative STEMI predictors, hemodi-
alysis was found to be another an independent correlates of 
in-hospital mortality in NSTEMI patients.
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